Author

A. Debin

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:benchmarking· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1

Frequent Co-Authors

D. Kim· 1 shared E. Perouzel· 1 shared M.-G. L. Lee· 1 shared S.-B. Hong· 1 shared S.-H. Lee· 1 shared S.-M. Kang· 1 shared Y.-H. Choi· 1 shared

Activity by Year

2023-2023 · peak 1/yr

Co-Author Collaboration Network

7 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

D. Kim

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

The defined TLR3 agonist, Nexavant, exhibits anti-cancer efficacy and potentiates anti-PD-1 antibody therapy by enhancing immune cell infiltration.

D. Kim, S.-H. Lee, Y.-H. Choi, S.-M. Kang, M.-G. L. Lee, S.-B. Hong, E. Perouzel, A. Debin

This paper evaluates Nexavant, a TLR3 agonist, showing enhanced anti-cancer effects and synergy with anti-PD-1 therapy through immune cell infiltration.

bioRxiv · Oct 25, 2023Immunology